First Week of IMVT February 2026 Options Trading

Immunovant (IMVT) option setups show a $23 put bid at $0.70 (sell-to-open implies a $22.30 net cost basis vs. the $26.59 spot), the $23 strike is ~14% OTM and greeks-implied odds of expiring worthless are ~75%, implying a 3.04% yield (17.63% annualized). On the call side, the $29 call is bid $1.20; selling a covered call against $26.59 stock would cap proceeds at $29 and yield 13.58% total if called at Feb 2026, with a 56% chance of expiring worthless and a 4.51% YieldBoost (26.15% annualized). Implied volatilities are 70% (put) and 64% (call) versus a trailing 12‑month volatility of 57%, making these yield-enhancement trades attractive to income-focused option sellers but with standard upside-capping and assignment risks.

Analysis

Market structure: The immediate winners are option premium sellers and yield-focused traders — the $23 put (bid $0.70) and $29 covered-call (bid $1.20) show implied vol (70%/64%) sitting above realized 57%, creating positive carry. Sellers benefit from a 75%/56% probability of expiry worthless per current analytics, while downside-biased holders and short-term momentum traders are exposed to biotechs' gap risk and binary event risk. Delta-hedging by dealers may increase intraday correlation between IMVT and broader biotech indices around expiries, amplifying flows.

Risk assessment: Tail risks include clinical/FDA failure, equity dilution (secondary raises), or a material adverse event that would blow back through implied vol and cause >40% drawdowns — plausible in 6–12 months. Timeline: immediate (days) — expiration flows and IV moves; short-term (weeks–months) — trial readouts, cash runway updates; long-term (quarters–years) — commercialization and revenue ramp or dilution. Hidden dependencies: liquidity of IMVT options, maker inventory, and potential block trades that can abruptly move IV; catalysts to watch: FDA correspondence, cash-burn commentary, and major buy/sell filings.

Trade implications: Direct tactical trades: selling the $23 put nets effective entry $22.30 (3.04% yield, 17.6% annualized) — appropriate sized 1–3% of portfolio with hard stop/defined-risk hedge (buy $20 put). Alternative: buy stock at $26.59 and sell Feb-2026 $29 call to cap upside at ~13.6% to expiry while collecting 4.51% yield boost. For volatility sellers prefer defined-risk credit spreads (sell $23 / buy $20) to limit tail loss; if you want asymmetric upside, run a 6–12 month long stock position funded by selling calls.

Contrarian angles: Consensus underestimates idiosyncratic upside if trial readouts are positive — a successful binary could rerate IMVT >50% within 3–6 months, making covered-call caps costly. Conversely, implied vol > realized by ~13–20ppt suggests carry for sellers but underprices tail risk; if IV spikes >90%/assignment occurs before dilution, short put sellers can be forced into expensive stock positions. Historical parallels: biotech post-approval rallies (e.g., other small immunology names) show rapid repricing — manage size and prefer defined-risk structures rather than naked exposure.

Key Decisions for Investors

• Establish a limited-size (1–3% portfolio) income-biased position by selling-to-open IMVT $23 puts (collect $0.70) with a defined hedge: simultaneously buy the $20 put to create a $3 wide put-credit spread; target net credit ≥ $0.50, maximum loss $2.50 per spread; close if IMVT > $28 or IV rises >25% from current level within 30 days.
• If willing to own equity, acquire IMVT at market (~$26.6) up to 1–2% portfolio and sell Feb-2026 $29 covered calls (collect $1.20) to target ~13.6% capped return to expiry; implement stop-loss on stock at 15% from entry if share price gap down or if company announces dilution plan.
• For shorter-duration, higher-probability income, implement defined-risk credit spreads (sell $23 / buy $20) sized so max capital at risk ≤2% portfolio; roll or unwind if IV compresses to ≤50% or if clinical/regulatory catalyst is announced within 30–90 days.
• For relative-value exposure, run a 6–12 month pair trade: long IMVT (1% position) vs short IBB (0.6–0.8% notional to approximate beta hedge) to isolate idiosyncratic upside from sector moves; close or rebalance on FDA/trial readout or if pair divergence >30%.